In late 2022, the FDA approved Genentech‘s Lunsumio (mosunetuzumab-axgb), a bispecific antibody for relapsed or refractory follicular lymphoma (R/R FL) patients who have received at least two prior systemic therapies. We recently caught up with Ginna Laport, VP, global head of lymphoma/CLL development franchise at Genentech, to learn more about how the drug could change the…
Roche’s bispecific antibody Lunsumio wins priority review from FDA for non-Hodgkin lymphoma
Roche (SIX:RO, ROG; OTCQX:RHHBY) has announced that it has accepted the company’s Biologics License Application (BLA) and granted priority review for Lunsumio (mosunetuzumab), a CD20xCD3 T-cell engaging bispecific antibody developed by the company’s Genentech subsidiary. In February, Biogen (Nasdaq:BIIB) said it would pay $30 million to exercise an option to participate in the development and…